Pitolisant治疗CPAP依从良好OSA患者残余日间过度嗜睡的随机试验
这项多中心、双盲、随机(3:1)、安慰剂对照、平行设计试验评估Pitolisant对CPAP依从良好但仍有残余日间过度嗜睡的中重度OSA患者的疗效与安全性。Pitolisant个体化滴定至最高20 mg/天,治疗12周,主要终点为意向治疗人群ESS评分变化。结果显示Pitolisant较安慰剂显著降低ESS(-2.6; 95%CI, -3.9至-1.4; P<.001),应答率更高(71.0% vs 54.1%; P=.013),但不良事件发生率更高(47.0% vs 32.8%; P=.03)。
要点
- Pitolisant可显著改善CPAP依从良好OSA患者的残余日间嗜睡。
- Pitolisant组ESS应答率71.0%,高于安慰剂组54.1%。
- Pitolisant组不良事件(主要为头痛和失眠)发生率高于安慰剂组。
核心结论
- Pitolisant作为CPAP辅助治疗可显著降低CPAP依从良好但仍残余嗜睡OSA患者的主观和客观嗜睡,并改善患者报告结局和医生报告疾病严重度。
研究设计与样本
- 多中心、双盲、随机(3:1)、安慰剂对照、平行设计试验,Pitolisant个体化滴定至最高20 mg/天,治疗12周。
- 主要终点为意向治疗人群ESS评分变化。
主要发现
- Pitolisant组ESS较安慰剂组显著降低(-2.6; 95%CI, -3.9至-1.4; P<.001)。
- Pitolisant组治疗应答率(ESS≤10或ESS变化≥3)显著高于安慰剂组(71.0% vs 54.1%; P=.013)。
- Pitolisant组不良事件发生率高于安慰剂组(47.0% vs 32.8%; P=.03),主要为头痛和失眠。
- 未报告心血管或其他显著安全性问题。
关键数值与推荐
- Pitolisant个体化滴定至最高20 mg/天,治疗12周。
- 主要终点为ESS评分变化;关键次要终点包括Oxford睡眠抵抗试验评估的觉醒维持、临床总体印象严重度量表、患者总体评价、EuroQoL生活质量问卷评分、Pichot疲劳问卷评分和安全性。
- 应答定义为ESS≤10或ESS变化≥3。
临床怎么用
- 对于CPAP依从良好但仍有残余日间过度嗜睡的中重度OSA患者,可考虑在CPAP基础上加用Pitolisant以改善嗜睡。
- 使用Pitolisant时需关注头痛和失眠等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Excessive daytime sleepiness (EDS) in individuals with OSA syndrome persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective histamine H3-receptor antagonist with wake-promoting effects. RESEARCH QUESTION: Is pitolisant effective and safe for reducing daytime sleepiness in individuals with moderate to severe OSA adhering to CPAP treatment but experiencing residual EDS? STUDY DESIGN AND METHODS: In a multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was titrated individually at up to 20 mg/day and taken over 12 weeks. The primary end point was change in the Epworth Sleepiness Scale (ESS) score in the intention-to-treat population. Key secondary end points were maintenance of wakefulness assessed by the Oxford Sleep Resistance Test, Clinical Global Impressions scale of severity, the patient's global opinion, EuroQoL quality-of-life questionnaire score, Pichot fatigue questionnaire score, and safety. RESULTS: Two hundred forty-four OSA participants (82.8% men; mean age, 53.1 years; mean Apnea Hypopnea Index with CPAP, 4.2/h; baseline ESS score, 14.7) were randomized to pitolisant (n = 183) or placebo (n = 61). ESS significantly decreased with pitolisant compared with placebo (-2.6; 95% CI, -3.9 to -1.4; P < .001), and the rate of responders to therapy (ESS ≤ 10 or change in ESS ≥ 3) was significantly higher with pitolisant (71.0% vs 54.1%; P = .013). Adverse event occurrence (mainly headache and insomnia) was higher in the pitolisant group compared with the placebo group (47.0% and 32.8%, respectively; P = .03). No cardiovascular or other significant safety concerns were reported. INTERPRETATION: Pitolisant used as adjunct to CPAP therapy for OSA with residual sleepiness despite good CPAP adherence significantly reduced subjective and objective sleepiness and improved participant-reported outcomes and physician-reported disease severity. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01071876; URL: www.clinicaltrials.gov; EudraCT N°: 2009-017248-14; URL: eudract.ema.europa.eu.
引用
- Pépin JL, Georgiev O, Tiholov R, et al. Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial. Chest. 2020. PMID: 33121980. doi:10.1016/j.chest.2020.09.281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。